We demonstrated that the attenuated CD26 staining in tumor‐associated stroma with an abundance of myofibroblasts is associated with poor outcomes for breast cancer patients, suggesting stromal CD26 staining to be a potentially novel prognostic marker. This evidence concerns the gene DPP4 and neoplasm.